An item on the third-quarter life-science venture data I’d initially planned to update over the weekend got unavoidably delayed, but is now available in updated form. At the risk of ruining the suspense, the major surprise is that venture capitalists appear to be abandoning the biotech sector in droves, with private equity and other non-VC sources of cash picking up the slack.